Wilson’s disease study backs Telomir-Zn for Telomir (NASDAQ: TELO)

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. filed an 8-K describing a press release about a new peer-reviewed preclinical study of its lead candidate Telomir-1 (Telomir-Zn) in Wilson’s disease. The study, published in Advances in Redox Research, used cellular systems and an ATP7B-deficient zebrafish model.

Telomir-Zn showed dose-dependent benefits across multiple endpoints, including reduced copper-associated oxidative stress, lower hepatic copper burden, improved liver injury biomarkers such as ALT, AST and bilirubin, attenuated intracellular calcium dysregulation, better locomotor performance, reduced hepatorenal tissue degeneration, and improved survival.

This is Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data supporting its mechanism of modulating intracellular copper and redox pathways. The company notes these pathways are also relevant to its Telomir-Zn program in Triple-Negative Breast Cancer, which has FDA IND clearance for a Phase 1/2 trial.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Publication date: May 20, 2026 Clinical stage: Phase 1/2

2 metrics

Publication date May 20, 2026 Peer-reviewed Telomir-Zn Wilson’s disease study in Advances in Redox Research

Clinical stage Phase 1/2 Planned Telomir-Zn trial in Triple-Negative Breast Cancer with FDA IND clearance

Key Terms

Wilson’s disease, Intracellular copper redox modulation, reactive oxygen species (ROS), Triple-Negative Breast Cancer, +2 more

6 terms

Wilson’s disease medical

"a zebrafish model of Wilson’s disease, including findings demonstrating reductions"

A rare inherited disorder in which the body cannot properly remove excess copper, causing copper to build up mainly in the liver and brain and leading to liver damage, movement or psychiatric symptoms. Investors care because the condition creates a defined market for diagnostics, drug development, and long‑term treatment or testing services; successful therapies or regulatory events can change revenue prospects for companies working on related diagnostics, medicines, or medical devices.

Intracellular copper redox modulation medical

"Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification"

reactive oxygen species (ROS) medical

"Reduction of copper-induced reactive oxygen species (ROS) amplification"

Reactive oxygen species (ROS) are highly reactive molecules produced naturally by cells that can damage DNA, proteins and cell structures when present in excess—think of them like biological 'rust' that wears down tissues. For investors, ROS matter because they are linked to many diseases, influence how drugs work or fail, and serve as safety signals or biomarkers in clinical trials, so levels of ROS can affect a therapy’s development, regulatory review and commercial prospects.

Triple-Negative Breast Cancer medical

"including its lead program in Triple-Negative Breast Cancer, for which the Company"

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

IND clearance regulatory

"has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2"

IND clearance is regulatory authorization that allows a company to begin testing an experimental drug in human clinical trials. Think of it as a safety-passport from regulators confirming enough preclinical evidence exists to move from lab work to people; for investors it marks a major development milestone that de-risks the program’s path to approval, unlocks value-driving data milestones, and often influences funding, partnerships, and stock value.

hepatorenal histopathological degeneration medical

"Reduction of hepatorenal histopathological degeneration"

Understanding 8-K Material Events →

false 0001971532 0001971532 2026-05-20 2026-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2026

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On May 20, 2026, Telomir Pharmaceuticals, Inc. issued a press release announcing publication of a peer-reviewed preclinical study titled “Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B-deficient zebrafish model of Wilson’s disease” in the journal Advances in Redox Research.

The publication reported preclinical findings evaluating Telomir-1 (Telomir-Zn) in cellular systems and a zebrafish model of Wilson’s disease, including findings demonstrating reductions in oxidative stress signaling, intracellular calcium dysregulation, hepatic copper accumulation, liver injury biomarkers, histopathological degeneration, and improvements in locomotor performance and survival outcomes.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1		Press Release dated May 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: May 20, 2026	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

Exhibit 99.1

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson’s Disease Model.

MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson’s disease model, supporting the biological activity of Telomir-Zn in Wilson’s disease. The study, titled “Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B-deficient zebrafish model of Wilson’s disease,” was published in Advances in Redox Research.

The publication reports that Telomir-Zn produced dose-dependent improvements across multiple endpoints in the preclinical Wilson’s Disease model, including reduced copper-associated oxidative stress, reduced hepatic copper burden, improved liver injury biomarkers, attenuated intracellular calcium dysregulation, improved locomotor function, reduced tissue degeneration, and enhanced survival.

The publication is available online at:

Advances in Redox Research Publication

Wilson’s disease is a rare genetic disorder caused by mutation in the ATP7B gene, resulting in impaired copper excretion and toxic copper accumulation in the liver, brain, and other organs. The condition leads to progressive oxidative stress, mitochondrial dysfunction, inflammation, and multi-organ tissue injury. Current standard-of-care treatments, primarily copper chelation agents, address systemic copper levels but do not directly target the downstream oxidative and mitochondrial injury pathways associated with disease progression.

According to the publication, Telomir-Zn demonstrated improvements across cellular and in vivo endpoints in the Wilson’s disease model, including:

	●	Reduction of copper-induced reactive oxygen species (ROS) amplification
	●	Attenuation of intracellular calcium dysregulation associated with oxidative stress signaling
	●	Preservation of metabolic viability under copper and peroxide challenge
	●	Reduction of hepatic copper accumulation
	●	Improvement in locomotor and neuromotor performance
	●	Reduction of liver injury biomarkers, including ALT, AST, and bilirubin
	●	Reduction of hepatorenal histopathological degeneration
	●	Improved survival in a dose-dependent manner in the Wilson’s disease model

The authors concluded that targeted modulation of labile intracellular copper pools disrupted ROS–Ca²⁺ feedback amplification, mitigated mitochondrial-associated tissue injury associated with copper overload, and produced dose-dependent improvements in survival.

This publication represents Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data across biochemical, functional, histological, and survival endpoints to the Company’s scientific package. The findings further support the mechanistic relevance of Telomir-Zn’s approach across pathways involving oxidative stress and dysregulated metal homeostasis, including its lead program in Triple-Negative Breast Cancer, for which the Company received FDA IND clearance in April 2026.

“This study demonstrated that modulation of intracellular copper-driven redox activity can disrupt ROS–Ca²⁺ amplification cascades associated with copper toxicity and mitochondrial injury.” said Dr. Itzchak Angel, Chief Scientific Advisor of Telomir Pharmaceuticals and corresponding author of the publication.

Dr. Angel continued, “The findings support intracellular metal homeostasis and redox regulation as potentially important biological pathways across diseases involving oxidative stress, mitochondrial dysfunction, and epigenetic dysregulation, including oncology.”

“This peer-reviewed publication is an important scientific milestone for Telomir-Zn. The data demonstrated meaningful improvements across a comprehensive set of endpoints in the Wilson’s disease model, and we believe the findings are consistent with the broader mechanistic profile of Telomir-Zn as we advance our lead program in Triple-Negative Breast Cancer toward Phase 1/2 clinical initiation,” said Erez Aminov, CEO of Telomir Pharmaceuticals.

Telomir Pharmaceuticals will continue evaluating the Wilson’s disease program and potential regulatory considerations alongside advancement of its lead TNBC program toward Phase 1/2 clinical initiation.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, aging, and degenerative disease. The Company’s lead program, Telomir-1 (Telomir-Zn), is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in Triple-Negative Breast Cancer. For more information, please visit https://telomirpharma.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified in the Company’s under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website, and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Contact Information

Krystina Quintana

Email: info@telomirpharma.com

Phone: (786) 396-6723

FAQ

What did Telomir Pharmaceuticals (TELO) announce in this 8-K filing?

Telomir Pharmaceuticals reported a peer-reviewed preclinical study of Telomir-Zn in Wilson’s disease. The study, in Advances in Redox Research, showed dose-dependent improvements in oxidative stress, liver biomarkers, tissue degeneration, locomotor function, and survival in an ATP7B-deficient zebrafish disease model.

What is Telomir-Zn and how is it being studied by TELO?

Telomir-Zn (Telomir-1) is Telomir’s lead small-molecule candidate designed to modulate intracellular metal homeostasis and epigenetic regulation. The new publication covers preclinical Wilson’s disease data and complements an FDA-cleared IND for a Phase 1/2 clinical trial in Triple-Negative Breast Cancer.

What key preclinical results did Telomir-Zn show in Wilson’s disease models?

In Wilson’s disease models, Telomir-Zn reduced copper-associated oxidative stress, lowered hepatic copper accumulation, improved liver injury biomarkers (ALT, AST, bilirubin), attenuated intracellular calcium dysregulation, improved locomotor and neuromotor performance, reduced hepatorenal histopathological degeneration, and increased survival in a dose-dependent manner.

Why is the Wilson’s disease publication important for Telomir (TELO)?

The Wilson’s disease study is Telomir-Zn’s first peer-reviewed publication in this indication. It adds independently validated preclinical data across biochemical, functional, histological, and survival endpoints, supporting the biological relevance of Telomir-Zn’s mechanism in diseases driven by oxidative stress and metal dysregulation.

How does this Wilson’s disease study relate to Telomir’s cancer program?

The study supports intracellular copper and redox modulation as relevant pathways across multiple diseases. Telomir highlights that these mechanisms align with its Telomir-Zn program in Triple-Negative Breast Cancer, which received FDA IND clearance for a Phase 1/2 clinical trial in April 2026.

What stage of development is Telomir Pharmaceuticals in for Telomir-Zn?

Telomir Pharmaceuticals describes itself as a clinical-stage biotechnology company. Its lead program Telomir-Zn has U.S. FDA IND clearance for a Phase 1/2 clinical trial in Triple-Negative Breast Cancer, while Wilson’s disease remains in the preclinical evaluation stage.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 25.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB